MRTX - ミラティ・セラピュ―ティックス (Mirati Therapeutics Inc.)

MRTXのニュース

   Myxoid Round Cell Liposarcoma Drug Market 2020 Emerging Players - Adaptimmune, Recordati SpA, Merck & Co., Inc, Novartis AG, Infinity Pharmaceuticals, Inc., Mirati Therapeutics, Inc  2020/10/01 19:07:55 OpenPR
Myxoid Round Cell Liposarcoma Drug Market Research Report By Therapy (Chemotherapy, Radiation Therapy and Others), Drugs (Trabectedin, Mechlorethamine and Others), Route of Administration (Injectable, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others),
   The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut  2020/10/01 12:18:26 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Annexon Inc (NASDAQ: ANNX ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) CTI BioPharma Corp (NASDAQ: CTIC ) I-Mab ADR (NASDAQ: IMAB ) Insulet Corporation (NASDAQ: PODD ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) (the blank check company announced a business combination with oncology-focused Vincera Pharma) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PMV Pharmaceuticals Inc (NASDAQ: PMVP ) PPD Inc (NASDAQ: PPD ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 30) Abeona Therapeutics Inc (NASDAQ: ABEO ) Alector Inc (NASDAQ: ALEC ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Neos Therapeutics Inc (NASDAQ: NEOS ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Pandion Therapeutics Inc (NASDAQ: PAND ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Amag Reportedly Pursued By Apollo's Covis Pharma AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) shares surged higher after a Bloomberg report said Apollo Management's Covis Pharma unit is in advanced talks to buy Amag.
   Mirati Therapeutics : Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study | MarketScreener  2020/09/20 12:25:00 MarketScreener
An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage… | September 20, 2020
   Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress  2020/09/18 12:00:00 PR Newswire
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or…
   BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR  2020/09/17 12:00:00 Business Wire
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation. The collaboration will investigate the potential of this combination to provide more effective and durable responses f
   Mirati Therapeutics : Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study | MarketScreener  2020/09/20 12:25:00 MarketScreener
An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage… | September 20, 2020
   Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress  2020/09/18 12:00:00 PR Newswire
SAN DIEGO, Sept. 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or…
   BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR  2020/09/17 12:00:00 Business Wire
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation. The collaboration will investigate the potential of this combination to provide more effective and durable responses f
   The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO  2020/09/17 11:59:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Myokardia Inc (NASDAQ: MYOK ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Revance Therapeutics Inc (NASDAQ: RVNC ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 16) PainReform Ltd (NASDAQ: PRFX ) Pandion Therapeutics Inc (NASDAQ: PAND ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Moderna Announces 2 R&D Collaborations For Up To $880M Moderna Inc (NASDAQ: MRNA ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) announced a three-year strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for cystic fibrosis.
   The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO  2020/09/16 12:00:28 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than doubled on its Wall Street debut) Repare Therapeutics Inc (NASDAQ: RPTX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) Histogen Inc (NASDAQ: HSTO ) PainReform Ltd (NASDAQ: PRFX ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SILENCE THERAPE/S ADR (NASDAQ: SLN ) Stocks In Focus Roche Gets Label Expansion For Cancer Screening Test Roche Holdings AG Basel (OTC: RHHBY ) announced FDA approval for the expanded use of CINtec PLUS Cytology, its first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus.
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal  2020/08/14 12:26:21 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Fulgent Genetics Inc (NASDAQ: FLGT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inozyme Pharma Inc (NASDAQ: INZY ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Natera Inc (NASDAQ: NTRA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Orthopediatrics Corp (NASDAQ: KIDS ) Penumbra Inc (NYSE: PEN ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Vaxcyte Inc (NASDAQ: PCVX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) Entera Bio Ltd (NASDAQ: ENTX ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX )(reacted to its second-quarter results) Lantern Pharma Inc. (NASDAQ: LTRN ) NanoVibronix Inc (NASDAQ: NAOV ) Recro Pharma Inc (NASDAQ: REPH ) Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX ) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate.
   Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights  2020/08/06 20:15:00 PR Newswire
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020. "Mirati is working to design, develop and deliver novel…
   Mirati (MRTX) Up 4.1% Since Last Earnings Report: Can It Continue?  2020/06/06 15:31:50 Zacks Investment Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer  2020/05/18 20:15:00 PR Newswire
SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020. Isan Chen, M.D., will step down as Chief Medical and…

calendar